Overview

A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma

Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate GMI-1271, a specific E-selectin antagonist, in multiple myeloma as adjunct to standard of care chemotherapy used to treat this disease.
Phase:
Phase 1
Details
Lead Sponsor:
GlycoMimetics Incorporated